A gold nanoparticle-linked glycoconjugate vaccine against Burkholderia mallei

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 11, Issue 2, 2015, Pages 447-456

  Gregory, Anthony E ^a   Judy, Barbara M ^c   Qazi, Omar ^d   Blumentritt, Carla A ^b   Brown, Katherine A ^d,e   Shaw, Andrew M ^a   Torres, Alfredo G ^b,c   Titball, Richard W ^a  

^a UNIVERSITY OF EXETER   (United Kingdom)

^b University of Texas Medical Branch School of Medicine   (United States)

^c UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^d UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^e UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Glanders; Glycoconjugate; Nanoparticles

Indexed keywords

BACTERIA; CARBOHYDRATES; GOLD NANOPARTICLES; METAL NANOPARTICLES; NANOPARTICLES; VACCINES;

BACTERIAL SPECIES; BURKHOLDERIA MALLEUS; GLANDERS; GLYCOCONJUGATE VACCINES; GLYCOCONJUGATES; GRAM-NEGATIVE BACTERIA; LIPOPOLYSACCHARIDES; MULTIDRUG RESISTANCE;

DRUG DELIVERY;

BACTERIAL PROTEIN; BACTERIAL VACCINE; BURKHOLDERIA MALLEI VACCINE; FLAGELLIN; GOLD NANOPARTICLE; HCP1 PROTEIN; LIPOPOLYSACCHARIDE; TETHC PROTEIN; UNCLASSIFIED DRUG; GLYCOCONJUGATE; GOLD; METAL NANOPARTICLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ARTICLE; BACTERIAL LOAD; BURKHOLDERIA THAILANDENSIS; CONTROLLED STUDY; FEMALE; GLANDERS; MOUSE; NONHUMAN; VACCINATION; WESTERN BLOTTING; ANIMAL; BURKHOLDERIA MALLEI; CHEMISTRY; DISEASE MODEL; DRUG EFFECTS; HUMAN; IMMUNOLOGY; INHALATIONAL DRUG ADMINISTRATION; MICROBIOLOGY; PATHOGENICITY;

BACTERIA (MICROORGANISMS); BURKHOLDERIA; BURKHOLDERIA MALLEI; BURKHOLDERIA THAILANDENSIS; MURINAE; NEGIBACTERIA;

ADMINISTRATION, INHALATION; ANIMALS; BACTERIAL VACCINES; BURKHOLDERIA MALLEI; DISEASE MODELS, ANIMAL; GLANDERS; GLYCOCONJUGATES; GOLD; HUMANS; LIPOPOLYSACCHARIDES; METAL NANOPARTICLES; MICE;

EID: 84922800412     PISSN: 15499634     EISSN: 15499642     Source Type: Journal    
DOI: 10.1016/j.nano.2014.08.005     Document Type: Article

References (54)

1. Prasad S., Cody V., Saucier-Sawyer J., Fadel T., Edelson R., Birchall M., et al. Optimization of stability, encapsulation, release, and cross-priming of tumor antigen-containing PLGA nanoparticles. Pharm Res 2012, 29(9):2565-2577.
2. Zaric M., Lyubomska O., Touzelet O., Poux C., Al-Zahrani S., Fay F., et al. Skin dendritic cell targeting via microneedle arrays laden with antigen-encapsulated poly-d,l-lactide-co-glycolide nanoparticles induces efficient antitumor and antiviral immune responses. ACS Nano 2013, 7(3):2042-2055.
3. Nembrini C., Stano A., Dane K.Y., Ballester M., van der Vlies A.J., Marsland B.J., et al. Nanoparticle conjugation of antigen enhances cytotoxic T-cell responses in pulmonary vaccination. Proc Natl Acad Sci U S A 2011, 108(44):E989-E997.
4. Tsoli M., Kuhn H., Brandau W., Esche H., Schmid G. Cellular uptake and toxicity of Au55 clusters. Small 2005, 1(8-9):841-844.
5. Connor E.E., Mwamuka J., Gole A., Murphy C.J., Wyatt M.D. Gold nanoparticles are taken up by human cells but do not cause acute cytotoxicity. Small 2005, 1:325-327.
6. Bhattacharya R., Mukherjee P. Biological properties of "naked" metal nanoparticles. Adv Drug Deliv Rev 2008, 60(11):1289-1306.
7. Li T., Guo L., Wang Z. Gold nanoparticle-based surface enhanced raman scattering spectroscopic assay for the detection of protein-protein interactions. Anal Sci 2008, 24:907-910.
8. Schmid G. Large clusters and colloids. Metals in the embryonic state. Chem Rev 1992, 92(8):1709-1727.
9. Wajanarogana S., Sonthayanon P., Wuthiekanun V., Panyim S., Simpson A.J., Tungpradabkul S. Stable marker on flagellin gene sequences related to arabinose non-assimilating pathogenic Burkholderia pseudomallei. Microbiol Immunol 1999, 43(11):995-1001.
10. Korch G., Parham G. Federal experts security advisory panel, recommendations concerning the select agent program 2011, [https://orise.orau.gov/emi/scapa/files/biosafety/fesap-recommendations-101102.pdf]. Services USDoAHaH (Ed.).
11. Whitlock G.C., Mark Estes D., Torres A.G. Glanders: off to the races with Burkholderia mallei. FEMS Microbiol Lett 2007, 277(2):115-122.
12. DeShazer D., Brett P.J., Woods D.E. The type II O-antigenic polysaccharide moiety of Burkholderia pseudomallei lipopolysaccharide is required for serum resistance and virulence. Mol Microbiol 1998, 30(5):1081-1100.
13. Burtnick M.N., Brett P.J., Woods D.E. Molecular and physical characterization of Burkholderia mallei O antigens. J Bacteriol 2002, 184(3):849-852.
14. Hamad M.A., Di Lorenzo F., Molinaro A., Valvano M.A. Aminoarabinose is essential for lipopolysaccharide export and intrinsic antimicrobial peptide resistance in Burkholderia cenocepacia †. Mol Microbiol 2012, 85(5):962-974.
15. Treviño S.R., Permenter A.R., England M.J., Parthasarathy N., Gibbs P.H., Waag D.M., et al. Monoclonal antibodies passively protect BALB/c mice against Burkholderia mallei aerosol challenge. Infect Immun 2006, 74(3):1958-1961.
16. Ngugi S.A., Ventura V.V., Qazi O., Harding S.V., Kitto G.B., Estes D.M., et al. Lipopolysaccharide from Burkholderia thailandensis E264 provides protection in a murine model of melioidosis. Vaccine 2010, 28(47):7551-7555.
17. Nelson M., Prior J.L., Lever M.S., Jones H.E., Atkins T.P., Titball R.W. Evaluation of lipopolysaccharide and capsular polysaccharide as subunit vaccines against experimental melioidosis. J Med Microbiol 2004, 53(12):1177-1182.
18. Qazi O., Prior J.L., Judy B.M., Whitlock G.C., Kitto G.B., Torres A.G., et al. Sero-characterization of lipopolysaccharide from Burkholderia thailandensis. Trans R Soc Trop Med Hyg 2008, 102(Suppl. 1):S58-S60.
19. Makela P.H. Conjugate vaccines-a breakthrough in vaccine development. Southeast Asian J Trop Med Public Health 2003, 34(2):249-253.
20. Kandil A.A., Chan N., Klein M., Chong P. Chemical synthesis of Haemophilus influenzae glycopeptide conjugates. Glycoconj J 1997, 14:13-17.
21. Kaplan S.L., Lauer B.A., Ward M.A., Wiedermann B.L., Boyer K.M., Dukes C.M., et al. Immunogenicity and safety of Haemophilus influenzae type b-tetanus protein conjugate vaccine alone or mixed with diphtheria-tetanus-pertussis vaccine in infants. J Pediatr 1994, 124(2):323-327.
22. Robbins J.B., Schneerson R. Polysaccharide-protein conjugates: a new generation of vaccines. J Infect Dis 1990, 161(5):821-832.
23. Sigurdardottir S.T., Vidarsson G., Gudnason T., Kjartansson S., Kristinsson K.G., Jonsson S., et al. Immune responses of infants vaccinated with serotype 6B pneumococcal polysaccharide conjugated with tetanus toxoid. Pediatr Infect Dis J 1997, 16(7):667-674.
24. Turkevich J., Stevenson P.C., Hillier J. A study of the nucleation and growth processes in the synthesis of colloidal gold. Discuss Faraday Soc 1951, 11:55-75.
25. Sinha K., Box M., Lalli G., Schiavo G., Schneider H., Groves M., et al. Analysis of mutants of tetanus toxin HC fragment: ganglioside binding, cell binding and retrograde axonal transport properties. Mol Microbiol 2000, 37(5):1041-1051.
26. Chart H. Methods in practical laboratory bacteriology 1994, CRC Press.
27. DuBois M., Gilles K.A., Hamilton J.K., Rebers P.A., Smith F. Colorimetric method for determination of sugars and related substances. Anal Chem 1956, 28(3):350-356.
28. Masuko T., Minami A., Iwasaki N., Majima T., Nishimura S.-I., Lee Y.C. Carbohydrate analysis by a phenol-sulfuric acid method in microplate format. Anal Biochem 2005, 339(1):69-72.
29. Williamson D.E., Sharp G.J.E., Eley S.M., Vesey P.M., Pepper T.C., Titball R.W., et al. Local and systemic immune response a microencapsulated sub-unit vaccine to for plague. Vaccine 1996, 14:1613-1619.
30. Lees A., Sen G., LopezAcosta A. Versatile and efficient synthesis of protein-polysaccharide conjugate vaccines using aminooxy reagents and oxime chemistry. Vaccine 2006, 24(6):716-729.
31. Gildersleeve J.C., Oyelaran O., Simpson J.T., Allred B. Improved procedure for direct coupling of carbohydrates to proteins via reductive amination. Bioconjug Chem 2008, 19(7):1485-1490.
32. Nierman W.C., DeShazer D., Kim H.S., Tettelin H., Nelson K.E., Feldblyum T., et al. Structural flexibility in the Burkholderia mallei genome. Proc Natl Acad Sci U S A 2004, 101(39):14246-14251.
33. Holden M.T.G., Titball R.W., Peacock S.J., Cerdeno-Tarraga A.M., Atkins T., Crossman L.C., et al. Genomic plasticity of the causative agent of melioidosis, Burkholderia pseudomallei. Proc Natl Acad Sci U S A 2004, 101(39):14240-14245.
34. Galyov E.E., Brett P.J., DeShazer D. Molecular insights into Burkholderia pseudomallei and Burkholderia mallei pathogenesis. Annu Rev Microbiol 2010, 64:495-517.
35. Zhang S., Feng S.H., Li B., Kim H.Y., Rodriguez J., Tsai S., et al. In vitro and In vivo studies on monoclonal antibodies with prominent bactericidal activity against Burkholderia pseudomallei and Burkholderia mallei. Clin Vaccine Immunol 2011, 18(5):825-834.
36. Jones S.M., Ellis J.F., Russell P., Griffin K.F., Oyston P.C. Passive protection against Burkholderia pseudomallei infection in mice by monoclonal antibodies against capsular polysaccharide, lipopolysaccharide or proteins. J Med Microbiol 2002, 51:1055-1062.
37. AuCoin D.P., Reed D.E., Marlenee N.L., Bowen R.A., Thorkildson P., Judy B.M., et al. Polysaccharide specific monoclonal antibodies provide passive protection against intranasal challenge with Burkholderia pseudomallei. PLoS One 2012, 7(4):17.
38. Nieves W., Asakrah S., Qazi O., Brown K.A., Kurtz J., Aucoin D.P., et al. A naturally derived outer-membrane vesicle vaccine protects against lethal pulmonary Burkholderia pseudomallei infection. Vaccine 2011, 29(46):8381-8389.
39. Peddayelachagiri B.V., Paul S., Makam S.S., Urs R.M., Kingston J.J., Tuteja U., et al. Functional characterization and evaluation of in vitro protective efficacy of murine monoclonal antibodies BURK24 and BURK37 against Burkholderia pseudomallei. PLoS One 2014, 9(3).
40. Charuchaimontri C., Suputtamongkol Y., Nilakul C., Chaowagul W., Chetchotisakd P., Lertpatanasuwan N., et al. Antilipopolysaccharide II: an antibody protective against fatal melioidosis. Clin Infect Dis 1999, 29:813-818.
41. Ho M., Schollaardt T., Smith M., Perry M., Brett P., Chaowagul W., et al. Specificity and functional activity of anti-Burkholderia pseudomallei polysaccharide antibodies. Infect Immun 1997, 65(9):3648-3653.
42. West T.E., Ernst R., Jansson-Hutson M., Skerrett S. Activation of Toll-like receptors by Burkholderia pseudomallei. BMC Immunol 2008, 9(1):46-56.
43. Honko A.N., Sriranganathan N., Lees C.J., Mizel S.B. Flagellin Is an effective adjuvant for immunization against lethal respiratory challenge with Yersinia pestis. Infect Immun 2006, 74(2):1113-1120.
44. Song L., Zhang Y., Yun N.E., Poussard A.L., Smith J.N., Smith J.K., et al. Superior efficacy of a recombinant flagellin:H5N1 HA globular head vaccine is determined by the placement of the globular head within flagellin. Vaccine 2009, 27(42):5875-5884.
45. Smith K.D., Andersen-Nissen E., Hayashi F., Strobe K., Bergman M.A., Barrett S.L., et al. Toll-like receptor 5 recognizes a conserved site on flagellin required for protofilament formation and bacterial motility. Nat Immunol 2003, 4(12):1247-1253.
46. McDermott P.F., Ciacci-Woolwine F., Snipes J.A., Mizel S.B. High-affinity interaction between gram-negative flagellin and a cell surface polypeptide results in human monocyte activation. Infect Immun 2000, 68(10):5525-5529.
47. Bates J.T., Honko A.N., Graff A.H., Kock N.D., Mizel S.B. Mucosal adjuvant activity of flagellin in aged mice. Mech Ageing Dev 2008, 129(5):271-281.
48. Gewirtz A.T., Navas T.A., Lyons S., Godowski P.J., Madara J.L. Cutting edge: bacterial flagellin activates basolaterally expressed TLR5 to induce epithelial proinflammatory gene expression. J Immunol 2001, 167(4):1882-1885.
49. Brett P.J., Mah D.C., Woods D.E. Isolation and characterization of Pseudomonas pseudomallei flagellin proteins. Infect Immun 1994, 62:1914-1919.
50. Williams S.G., Varcoe L.T., Attridge S.R., Manning P.A. Vibrio cholerae Hcp, a secreted protein coregulated with HlyA. Infect Immun 1996, 64(1):283-289.
51. Pukatzki S., Ma A.T., Revel A.T., Sturtevant D., Mekalanos J.J. Type VI secretion system translocates a phage tail spike-like protein into target cells where it cross-links actin. Proc Natl Acad Sci U S A 2007, 104(39):15508-15513.
52. Whitlock G.C., Deeraksa A., Qazi O., Judy B.M., Taylor K., Propst K.l., et al. Protective response to subunit vaccination against intranasal Burkholderia mallei and B. pseudomallei challenge. Procedia Vaccinol 2010, 2(1):73-77.
53. Easton A., Haque A., Chu K., Patel N., Lukaszewski R.A., Krieg A.M., et al. Combining vaccination and postexposure CpG therapy provides optimal protection against lethal sepsis in a biodefense model of human melioidosis. J Infect Dis 2011, 204(4):636-644.
54. Sarkar-Tyson M., Smither S.J., Harding S.V., Atkins T.P., Titball R.W. Protective efficacy of heat-inactivated B. thailandensis, B. mallei or B. pseudomallei against experimental melioidosis and glanders. Vaccine 2009, 27(33):4447-4451.